

FREEDOM-TO-OPERATE (FTO) EXPLORATION WITH CAS IP FINDER®


Rob Austin, ACS International, representing CAS

João Jacinto, CAS IP Services (EMEA) – Represented by FIZ Karlsruhe

FTO Exploration with CAS IP Finder

How it fits into in a professional IP search workflow


- Introduction
- FTO vs Patentability: Brief overview
- Search example: 5-CNAC
- CAS IP Finder: Search and results review
- PatBase: Import CAS IP Finder PNs and search steps
- Analysis, record selection, reporting
- Closing remarks, Q&A



A Search Solution for Every User


Five search pathways. Choose the one that fits you.

Command-line




For power users. Full STN® syntax and multi-file precision searching. The trusted method experts rely on.

Point-and-click Query Builder




For everyday searchers. A straightforward interface that delivers STN precision without command-line syntax.

Structure Search




For structure search practitioners. CAS proprietary structure drawing tool.

Exploratory Search



For free-text discovery. Paste an abstract, claim, or press release, and proprietary AI finds the most similar patent and non-patent literature.

CAS Newton





For conversational discovery. Science-smart agentic AI made for the IP searcher that takes questions, builds the search strategy, and returns answers.

CAS NewtonSM

Ask in plain language. CAS Newton runs the search. You stay in control.

1. Ask a question the way you speak in your language.

2. CAS Newton builds commands and runs the search.



All access, one ask

CAS Newton searches every database you license: patents, literature, structures, and sequences, in a single conversation.

Easy to use

No syntax, no database picking. Talk to CAS Newton the way you talk to colleagues.

Every command is visible


CAS Newton shows the files it picked and the commands it built. Experts stay in control.

Insights, not just results

Natural-language summaries turn 10,000 hits into clear, actionable insights.

CAS IP Finder: FTO Workflow with PatBase

CAS IP Finder: Search and retrieval. PatBase: Search text, collect, analyze and report.



CAS IP Finder is key part of the comprehensive FTO workflow

FTO vs Patentability Search

Why does it matter?

Freedom to operate (FTO) search



- Search for patents or pending applications which might protect/cover a proposed product or process
 - Aim: to help avoid potential patent infringement
- Last 20 years (25 years for pharma)
- Main focus: **Claimed** features
- High **comprehensiveness** needed

Patentability search



- Search for the closest “prior art” patent or non patent literature to a proposed (or already filed) patent application
 - Aim: to help determine if the application would be granted
- Any time up to the filing date
- Main focus: Novelty and Inventiveness
- The **closest prior art** is needed

What are the Main Challenges in FTO Searching?



FTO Search Example

A client intends to commercialize a pharmaceutical product containing 5-CNAC as a permeation enhancer. Which active patents could impact freedom to operate in the IP5 jurisdictions, including compound, Markush, formulation, use and process-type claims?

After discussing with the client...

The search need is clarified

- Patents with specific claims to 5-CNAC
- Broader Markush structures which may encompass 5-CNAC
- Formulation claims involving 5-CNAC
- Currently in force in the IP5 jurisdictions

The search scope is defined

- Compound patents
- Markush claims
- Formulation patents
- Method-of-use patents
- Process patents
- *Exclude*: Device patents and passing mentions in long ingredient lists


5-CNAC – Drug Absorption Enhancer

N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC)

204852-67-5

Octanoic acid, 8-[(5-chloro-2-hydroxybenzoyl)amino]- (CA INDEX NAME)

C₁₅ H₂₀ Cl N O₄




5-CNAC

- Fatty-acid benzamide delivery agent; not pharmacologically active itself
- Enhances oral absorption of co-administered drugs, especially peptides, e.g., calcitonin

FTO Exploration with CAS IP Finder

How it fits into in a professional IP search workflow

- Introduction
- FTO vs Patentability: Brief overview
- Search example: 5-CNAC
- **CAS IP Finder: Search and results review**
- PatBase: Import CAS IP Finder PNs and search steps
- Analysis, record selection, reporting
- Closing remarks, Q&A



CAS IP Finder: Search and Results Review

Overview of example workflow steps

- CAS Newton: Your AI assistant for IP
- Structure search in CAS Registry
- Structure search in the CAS Markush Database – MARPAT
- Repeat in Derwent databases: DCR and DWPIM
- Extending and refining with text searching
- Transfer of answer set to PatBase

CAS Newton: A Great Place to Start

Find patents using REGISTRY and CPlus on N-(5-Chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) as a drug penetration enhancer. Include all multi-component ... X

Find patents using REGISTRY and CPlus on N-(5-Chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) as a drug penetration enhancer. Include all multi-component registrations. Provide a table of results by assignee and drug topic area.

9:03:27 PM



FILE REGISTRY; E 5-CNAC/CN; E N-(5-Chlorosalicyloyl)-8-aminocaprylic acid/CN



I've confirmed the parent 5-CNAC entry and its sodium salts; now I'm checking whether REGISTRY carries additional multicomponent registrations built from that component.

S E3-E5; D L1 1-3 RN CN MF



I've got the REGISTRY component fields now, so I'm pulling the multicomponent records that explicitly contain the 5-CNAC parent as a component.

S 204852-67-5/CRN AND NC>=2; D L2 1-20 RN CN CRN CCI MF



I'm moving into CPlus now: first I'll get the full patent set for the parent plus all related multicomponent RNs, then I'll separate the penetration-enhancer use cases from the broader chemistry.

L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2026 ACS on STN
RN 300718-77-8 REGISTRY
CN Octanoic acid, 8-[(5-chloro-2-hydroxybenzoyl)amino]-, sodium salt (1:1)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Octanoic acid, 8-[(5-chloro-2-hydroxybenzoyl)amino]-, monosodium salt
(9CI)
OTHER NAMES:
CN 5-CNAC monosodium salt
CN **N-(5-Chlorosalicyloyl)-8-aminocaprylic acid monosodium salt**
MF C15 H20 Cl N O4 . Na

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2026 ACS on STN
RN 300718-75-6 REGISTRY
CN Octanoic acid, 8-[(5-chloro-2-hydroxybenzoyl)amino]-, sodium salt (1:2)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Octanoic acid, 8-[(5-chloro-2-hydroxybenzoyl)amino]-, disodium salt (9CI)
OTHER NAMES:
CN 5-CNAC disodium salt
CN **N-(5-Chlorosalicyloyl)-8-aminocaprylic acid disodium salt**
MF C15 H20 Cl N O4 . 2 Na

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2026 ACS on STN

Close

☒ Show Command Line Panel

CAS Newton: Your AI Assistant for IP

Find patents using REGISTRY and CAPlus on N-(5-Chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) as a drug penetration enhancer. Include all multi-component ... X

Overall status picture

- 66 records have at least one alive/transitional member
- 2 records are indeterminate-only
- 36 records are dead-only
- 0 records in this set lacked a status bucket

Status by company

Company / standardized owner (UOS)	Total records	Has alive / transitional member	Indeterminate-only	Dead-only
Novo Nordisk	21	4	1	16
Novartis	14	8	1	5
Nordic Bioscience	12	9	0	3
Entera Bio Ltd	9	9	0	0
Guangzhou Dazhou Biomedicine	4	4	0	0
Cyprumed GmbH	4	3	0	1
Jiangsu Hengrui Medicine	4	3	0	1

L4 ANSWER 95 OF 104 CAPLUS COPYRIGHT 2026 ACS on STN

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

AN 2003:154280 CAPLUS [Full-text](#)

DN 138:210303

TI 5-CNAC as **oral delivery** agent for parathyroid hormone fragments

IN Azria, Moise; Bateman, Simon David

PA **Novartis AG**, Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
-----	----	-----	-----	-----
WO 2003015822	A1	20030227	English	PDF PDF+ Interactive
BR 2002011932	B1	20161206	Portuguese	PDF
CN 1543357	A	20041103		PDF
CN 1279981	C	20061018	Chinese	PDF
JP 4959917	B2	20120627	Japanese	PDF
CO 5560586	A2	20050930	Spanish	PDF
US 20120088725	A1	20120412	English	PDF
US 9272040	B2	20160301	English	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Close

☒ Show Command Line Panel

Structure Search in CAS Registry

Structure search: Draw New

 IP Finder
powered by STN



Hello, Robert

 Keyword Search  **Structure Search**  Exploratory Search

 Draw New  Select Existing

Command Line Preview

1

2

Search

Structure Search in CAS Registry

Structure Editor: Generate structure from RN, save, and upload

The screenshot displays the CAS Structure Editor interface. The main window shows the chemical structure of 2-(4-chlorophenyl)-N-octylbenzamide, which consists of a benzamide core with an octyl chain on the nitrogen and a 4-chlorophenyl group on the carbonyl carbon. The title bar reads "Structure Editor - 5-CNAC". The top toolbar includes icons for file operations, editing, and a search icon. A text box in the toolbar contains the CAS Registry Number "204852-67-5", which is circled in blue. The right sidebar, titled "Attribute Values", lists various chemical attributes and their values: Bond Type (Chain | Ring | Ring / Chain), Bond Value (Exact | Normalized | Exact / Normalized), Node Type (Chain | Ring | Ring / Chain), Generic Definition (Saturated | Unsaturated, Linear | Branched, Monocyclic | Polycyclic, 1 hetero atom | 2+ hetero atoms, 1-6 carbons | 7+ carbons), Match Level (Atom | Class | Any), Element Count Level (Limited | Unlimited), Ring Isolation (Isolated | Isolated / Embedded), Stereochemistry (Relative(default) | Absolute(default), Relative | Absolute | Racemic), and Other Node Attributes (Mass, Valency, Hydrogen Count, Non-Hydrogen Count, Element Count). The bottom of the editor shows the molecular formula "C₁₅H₂₀ClNO₂ (313.78)", a zoom slider set to 130%, and buttons for "Upload", "Save", "Save As", and "Cancel".

Structure Editor - 5-CNAC

204852-67-5

Molecular Formula: C₁₅H₂₀ClNO₂ (313.78)

Zoom: 130%

Upload Save Save As Cancel

Attribute Values

- Bond Type: Chain | Ring | Ring / Chain
- Bond Value: Exact | Normalized | Exact / Normalized
- Node Type: Chain | Ring | Ring / Chain
- Generic Definition: Saturated | Unsaturated, Linear | Branched, Monocyclic | Polycyclic, 1 hetero atom | 2+ hetero atoms, 1-6 carbons | 7+ carbons
- Match Level: Atom | Class | Any
- Element Count Level: Limited | Unlimited
- Ring Isolation: Isolated | Isolated / Embedded
- Stereochemistry: Relative(default) | Absolute(default), Relative | Absolute | Racemic
- Other Node Attributes: Mass, Valency, Hydrogen Count, Non-Hydrogen Count, Element Count

Structure Search in CAS Registry

Select to run the search in REGISTRY

The screenshot displays the CAS Structure Editor - 5-CNAC interface. A central dialog box titled "Select Structure Database" is open, prompting the user to "Select one of the following databases to search structure." The dialog lists six options, each with a radio button and an information icon:

- ☐ CASREACT The Chemical Abstracts Reaction Database
- ☐ DCR DERWENT CHEMISTRY RESOURCE
- ☐ DWPIM DERWENT MARKUSH RESOURCE 1961 TO DATE
- ☐ MARPAT CAS Markush Database
- ☐ REAXYFILESU SUBSTANCES TO THE REFERENCES OF REAXYFILESU, 1771-
- ☒ REGISTRY CAS REGISTRY File

At the bottom of the dialog are "Continue" and "Cancel" buttons. The background interface includes a top toolbar with icons for file operations and a search bar labeled "Enter a CAS Registry Number, SMILES, or InChI...". On the left is a vertical toolbar with drawing tools. The main workspace shows a chemical structure of 5-chloro-2-nitrobenzoic acid with the molecular formula C15H20ClNO4 (313.78). On the right, the "Attribute Values" panel lists various search criteria such as Bond Type, Bond Value, Node Type, Generic Definition, Match Level, Element Count Level, Ring Isolation, Stereochemistry, and Other Node Attributes.

Structure Search in CAS Registry

Select closed substructure (CSS) full search

CAS IP Finder powered by STN

Help My Files Robert Austin


Hello, Robert

Q Keyword Search **Structure Search** Exploratory Search

L1 STRUCTURE UPLOADED

Closed Substructure Substructure (SSS) Exact (EXA) Family (FAM) Closed Substructure (CSS)

Full X



Command Line Preview

```
1 FILE REGISTRY;  
2 SEARCH L1 CSS FULL;
```


Search

Search History

Sort: Descending

L1

REGISTRY STRUCTURE UPLOADED



What's New

September 10
CASFORMULATION, CASBIOACTIVITY, and Patent Status Enhancements

July 23
CAS Newton Conversation History, CAS Newton Ultimate Owner and Derwent Enhancements

June 12

Find Training | Contact Us | Legal

Structure Search in CAS Registry

Review REGISTRY hits; Retrieve CPlus patents

CAS IP Finder powered by STN

Help My Files Robert Austin

Back to Home

Refine Search Visualize Results

Database: REGISTRY

L2 SEARCH L1 CSS FULL

Sort: Descending 22 Results

REGISTRY SEARCH L1 CSS FULL

View Results

L1

REGISTRY STRUCTURE UPLOADED

L2 RESULTS for "L1 CSS FULL"

REGISTRY (22)

Sort: Registry Number Descending

Share With SciFinder

Get Related Documents

Related documents will be retrieved from the CAPLUS database.

☐ All documents (Patents and Non-Patent Literature)

☒ Patents only

☐ Non-Patent Literature only

Continue Cancel

44985-71-9

Show 10 per page Previous 1 2 3 Next

Copyright 2026 ACS on STN REGISTRY

Structure Search in CAS Registry

Review CAPLUS records retrieved via the structure search

CAS IP Finder powered by STN

Help My Files Robert Austin

Back to Home

L3 Results for "L2 AND PATENT/DT"


CAPLUS (110) Sort: Accession Number Descending

Create Report Share With SciFinder

3 Patent | 2026

Drug delivery composition and therapeutic uses for diabetes

Abstract: A pharmaceutical compn. for delivering a polypeptide, a prepn. method therefor, and a use for treating diabetes and obesity thereof. The compn. has excellent bioavailability.



3

Drug delivery composition and therapeutic uses for diabetes

Full-Text PatentPak PDF Register Links

Accession Number: PDF 405

Document Number: Interactive PDF+

Author/Inventor: Chen, Hao; Xu, Jiajia; Zhang, Qiang; Zhao, Lanjie

Patent Assignee: Jiangsu Hengrui Pharmaceuticals Co., Ltd., Peop. Rep. China

Ultimate Owner: JIANGSU HENGRUI MEDICINE CO., LTD.

Ultimate Owner: liangsu Hengrui Medicine

Show 10 per page Previous 1 2 3 4 5 ... 11 Next

Copyright 2026 ACS on STN CAPLUS

Open the PatentPak interactive PDF to jump to the location of the substance in the original.

<https://www.stn.org/stn/#>


PatentPak Interactive PDF

Jump directly to the location of the substance in the original

CAS PatentPak

WO 2026092429 A1


204852-67-5



Claim Locations (1)

Page 66


183990-65-0



Claim Locations (1)

Page 66

387825-03-8



Claim Locations (1)

Page 66

30

6、根据权利要求 1-4 中任一项所述的药物组合物，其中式 (B) 所示的化合物选自以下任一结构所示的化合物，


64

WO 2026/092429


PCT/CN2025/130461



式 C;



式 D;



66

88

↑

↓

🔍

+

-

Structure Search in CAS MARPAT

Structure Editor: Generate structure from RN, save, and upload

The screenshot displays the CAS Structure Editor interface. The main window shows a chemical structure of 4-chloro-N-(8-oxooctyl)benzamide. The molecular formula is $C_{15}H_{20}ClNO_4$ (313.78). The interface includes a toolbar with various drawing and editing tools, a search bar with the ID 204852-67-5, and a sidebar with element and ring selection buttons. A pop-up window titled 'Attribute Values' is open, showing search settings for Bond Type, Bond Value, Node Type, Generic Definition, Match Level, Element Count Level, Ring Isolation, Stereochemistry, and Other Node Attributes. A text box in the foreground explains the default Markush search MATCH levels.

Structure Editor - 5-CNAC

204852-67-5

Draw or change atoms or bonds.

Molecular Formula: $C_{15}H_{20}ClNO_4$ (313.78)

Upload Save Save As Cancel

Attribute Values

- Bond Type: Chain | Ring | Ring / Chain
- Bond Value: Exact | Normalized | Exact / Normalized
- Node Type: Chain | Ring | Ring / Chain
- Generic Definition: Saturated | Unsaturated, Linear | Branched, Monocyclic | Polycyclic, 1 hetero atom | 2+ hetero atoms, 1-6 carbons | 7+ carbons
- Match Level: Atom | Class | Any
- Element Count Level: Limited | Unlimited
- Ring Isolation: Isolated | Isolated / Embedded
- Stereochemistry: Relative(default) | Absolute(default), Relative | Absolute | Racemic
- Other Node Attributes: Mass, Valency, Hydrogen Count, Non-Hydrogen Count, Element Count

The default Markush search MATCH levels are used:

- Chain nodes: CLASS
- Ring nodes: ATOM

Structure Search in CAS MARPAT

Select to run the search in MARPAT

The screenshot displays the CAS IP Finder Structure Editor interface. A central dialog box titled "Select Structure Database" is open, prompting the user to "Select one of the following databases to search structure." The dialog lists six options:

- ☐ CASREACT: The Chemical Abstracts Reaction Database
- ☐ DCR: DERWENT CHEMISTRY RESOURCE
- ☐ DWPIIM: DERWENT MARKUSH RESOURCE 1961 TO DATE
- ☒ MARPAT: CAS Markush Database
- ☐ REAXYSFILESU: SUBSTANCES TO THE REFERENCES OF REAXYSFILEBI, 1771-
- ☐ REGISTRY: CAS REGISTRY File

Buttons for "Continue" and "Cancel" are at the bottom of the dialog. The background interface shows the "Structure Editor - 5-CNAC" window with a chemical structure of 5-chloro-2-nitrobenzoic acid. The molecular formula is $C_7H_5ClNO_2$ (313.78). The right sidebar contains "Attribute Values" for Bond Type, Bond Value, Node Type, Generic Definition, Match Level, Element Count Level, Ring Isolation, Stereochemistry, and Other Node Attributes.

Structure Search in CAS MARPAT

Select closed substructure (CSS) full search

CAS IP Finder powered by STN

Help My Files Robert Austin


Hello, Robert

Q Keyword Search **Structure Search** Exploratory Search

L4 STRUCTURE UPLOADED

Closed Substructure Substructure (SSS) **Closed Substructure (CSS)**

Full X



Command Line Preview

```
1 FILE MARPAT;  
2 S L4 CSS FULL;
```


Search

Search History

Sort: Descending

L4

MARPAT STRUCTURE UPLOADED



L3 110 Results

CAPLUS SEARCH L2 AND PATENT/DT

View Results

L2 22 Results

REGISTRY SEARCH L1 CSS FULL

View Results

Find Training | Contact Us | Legal

<https://www.stn.org/stn/#>

Structure Search in CAS MARPAT

Review MARPAT records retrieved via the structure search

CAS IP Finder powered by STN

Help My Files Robert Austin

Back to Home


L5 Results for "L4 CSS FULL"

MARPAT (61) Sort: Accession Number Descending

Create Report Get Related Documents

186:275211

MSTR 3 Assembled



63: alkylene <containing 2-16 C> (opt. substd.)
Patent location: claim 2
Note: or pharmaceutically acceptable salts

Full-Text PatentPak PDF PDF Interactive PDF+

Accession Number: 186:275211
Source: 186:275211, 68pp.
Other Source: CASFORMULTNS 2024:853655

Markush Structure

MSTR 3 Assembled

Show 10 per page Previous 1 2 3 4 5 ... 7 Next

Open the PatentPak PDF to jump to the Claims in the original.

Copyright 2026 ACS on STN MARPAT

Structure Search in CAS MARPAT

Jump to the location of the Markush claim in the original

CAS IP Finder powered by STN

Back to Home


L5 Results for "L4 CSS FULL"

MARPAT (61) Sort: Accession Number

Create Report Get Related Documents

186:275211

MSTR 3 Assembled



63: alkylene <containing 2-16 C> (opt. substd.)


Patent location: claim 2

Note: or pharmaceutically acceptable salts

10 per page Previous 1 2 3 4 5 ... 7 Next

Copyright 2026 ACS on STN MARPAT

caspatdoc:WO-2024077... 58 / 68 170%




Formula I.

2. The pharmaceutical composition of claim 1, further comprising:

(a) an aliphatic acid of Formula II: R_2COOH , wherein R_2 represents an group, or a pharmaceutically acceptable salt thereof; or

(b) a compound of Formula III:



Formula III

or a pharmaceutically acceptable salt thereof, wherein:

L^1 is a substituted or unsubstituted C_2 - C_{16} alkylene, or substituted or unsubstituted C_2 - C_{16} alkenylene;

n is an integer selected from 0, 1, 2, 3, or 4; and


G^1 at each occurrence is independently OH, NH_2 , $NH(C_{1-4} \text{ alkyl})$, $N(C_{1-4} \text{ alkyl})(C_{1-4} \text{ alkyl})$, halogen (e.g., Cl), C_{1-4} alkyl, or C_{1-4} alkoxy (e.g.,

Derwent World Patents Index (DWPI)

Repeat the CAS workflow using DCR, DWPIM, and WPINDEX


Self-emulsifying nanoparticles useful in medicine, health functional food, and cosmetic delivery systems for delivering active ingredients comprises active-ingredient-containing nanoparticles and self-emulsifying system, which sp...

Abstract: KR 2026108487 A UPAB 20260902
NOVELTY - Self-emulsifying nanoparticles (SENPs) having two-layer structure comprises (a) active-ingredient-containing nanoparticles (NP), and (b) self-emulsifying system (SES), which spontaneously emulsify upon dilution...



Preparation of salicyloyl-amino acid derivatives comprises coupling oligo-salicylate with amino acid, useful in delivery of biologically active agents

Abstract: WO 9850341 A1 UPAB 20050520
NOVELTY - Preparation of salicyloylamino acid (I) comprises reacting an oligosalicylate and an amino acid to give (I).
USE - Salicyloylamino acid derivatives are useful in the delivery of biologically active agents....



16 LOW,MID

DCR = *Derwent Chemistry Resource*

DWPIM = *Derwent Markush Resource*

WPINDEX = *Derwent World Patents Index (DWPI)*

Extending and Refining with Text Searching

Search terms for both topic area and the substance

Example CAS IP Finder Search Queries

- (skin or dermis or dermal or epidermis or epidermal or transdermal or intestine or intestinal or gastrointestinal or duodenum or jejunum or ileum or colon or epithelium or epithelial or transepithelial or stomach or mucosa or mucosal or transmucosal)(3a)(enhanc? or improv?)
- (permeation or penetration or absorption or (drug or pharmaceutical or active(w)(agent or substance)) (3a)deliver?)(3a)(enhanc? or improv? or system)
- 5-CNAC or (chlorosalicyloyl or chloro salicyloyl or chloro(3a)hydroxy(3a)benzoyl or hydroxy(3a)chlorobenzoyl or chloro(3a)hydroxybenzoyl)(2w) (aminocaprylic or aminocaprylate or aminooctanoic or aminooctanoate or amino(w)(caprylic or caprylate or octanoic or octanoate))

CAS Controlled Terminology (“Concepts”)

Search queries (left) incorporate several CAS concepts:

- PERMEATION ENHANCERS
- SKIN PENETRATION ENHANCERS
- TRANSDERMAL DRUG DELIVERY SYSTEMS
- MUCOSAL DRUG DELIVERY SYSTEMS

CAS IP Finder text search settings

Search queries (left) assume these personal settings are **ON**:

- SET PLURALS ON
- SET ABBREVIATION ON
- SET SPELLINGS ON
- SET SFIELDS BI CLM

Combine Structure and Text Searches

CAS IP Finder powered by STN

Help My Files Robert Austin

Transcript ON FTO exploration with CAS IP Finder 20260917

File WPINDEX

FILE 'CAPLUS' ENTERED AT 16:31:10 ON 17 SEP 2026

SET SFIELDS BI CLM

SET ABBREVIATION ON

SET PLURALS ON

SET SPELLINGS ON

L11 61 S L5

L12 108 5-CNAC OR (CHLOROSALICYLOYL OR CHLORO SALICYLOYL OR CHLORO(3A)H

L13 98 S L12 AND P/DT

L14 164 S L3 OR L11 OR L13

L15 963928 (PERMEATION OR PENETRATION OR ABSORPTION OR (DRUG OR PHARMACEUT

L16 148507 (SKIN OR DERMIS OR DERMAL OR EPIDERMIS OR EPIDERMAL OR TRANSFER

L17 129 S L14 AND (L15 OR L16)

FILE 'WPINDEX' ENTERED AT 16:51:06 ON 17 SEP 2026

FILE 'WPINDEX' ENTERED AT 16:51:55 ON 17 SEP 2026

SET SFIELD BI CLM

L18 103 5-CNAC OR (CHLOROSALICYLOYL OR CHLORO SALICYLOYL OR CHLORO(3A)H

L19 131 L8 OR L10 OR L18

L20 153692 (PERMEATION OR PENETRATION OR ABSORPTION OR (DRUG OR PHARMACEUT

L21 96574 (SKIN OR DERMIS OR DERMAL OR EPIDERMIS OR EPIDERMAL OR TRANSFER

L22 63 S L19 AND (L20 OR L21)

History Project CAS Lexicon Databases

Session

Entered WPINDEX 16:51:55 ON 17 SEP 2026

L18 103 5-CNAC OR (CHLOROSALICYLOYL OR CHLORO SALICYLOYL OR CHLORO(3A)H

L19 131 L8 OR L10 OR L18

L20 153692 (PERMEATION OR PENETRATION OR ABSORPTION OR (DRUG OR PHARMACEUT

L21 96574 (SKIN OR DERMIS OR DERMAL OR EPIDERMIS OR EPIDERMAL OR TRANSFER

L22 63 S L19 AND (L20 OR L21)

CAS content.

DWPI content.

CAS Newton with CAS NewtonSM experience helps you quicker. Learn more. Ask CAS Newton

Submit Draw Scripts

⇒ DUP IDE L17 L22


L17 = CAS results

L22 = DWPI results

FTO Exploration with CAS IP Finder

How it fits into in a professional IP search workflow

- Introduction
- FTO vs Patentability: Brief overview
- Search example: 5-CNAC
- CAS IP Finder: Search and results review
- **PatBase: Import CAS IP Finder PNs and search steps**
- Analysis, record selection, reporting
- Closing remarks, Q&A



Transfer of Answer Sets to PatBase

- To transfer the results found in CAS IP Finder, you can take the following approach:
 - => DUP IDE L_x (CAPLUS) L_y (WPINDEX)
 - => ANALYZE L_z PNK.B
 - => D 1- DELIM
- The delimited PN list can be taken from the transcript provided at the end of your CAS IP Finder session

Merge Results and Display a Delimited List of PNs

CAS IP Finder powered by STN

Help My Files Robert Austin

Transcript ON FTO exploration with CAS IP Finder 20260917

Multiple Files

=> DUP IDE L17 L22

FILE 'CAPLUS' ENTERED AT 17:08:45 ON 17 SEP 2026
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2026 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPINDEX' ENTERED AT 17:08:45 ON 17 SEP 2026
COPYRIGHT (C) 2026 CLARIVATE
PROCESSING COMPLETED FOR L17
PROCESSING COMPLETED FOR L22

L23 192 DUP IDE L17 L22 (INCLUDES 54 SETS OF DUPLICATES)
ANSWERS '1-129' FROM FILE CAPLUS
ANSWERS '130-192' FROM FILE WPINDEX

=> ANA PNK.B

L24 ANALYZE L23 1- PNK.B : 136 TERMS

=> D DELIM 1-

L24 ANALYZE L23 1- PNK.B : 136 TERMS

1;2;2;1.04;CN111617257 A
2;2;2;1.04;CN111617258 A

=> LOG H

Submit Draw Scripts

History Project CAS Lexicon Databases

Session

L17 15592 (PENETRATION OR
PENETRATION OR ABSORPTION
OR (DRUG OR PHARMACEUT

L21 96574 (SKIN OR DERMIS OR
DERMAL OR EPIDERMIS OR
EPIDERMAL OR TRANSFER

L22 63 S L19 AND (L20 OR L21)

Entered Multiple files 17:08:45 ON 17 SEP 2026

L23 192 DUP IDE L17 L22
(INCLUDES 54 SETS OF
DUPLICATES)

L24 ANALYZE L23 1- PNK.B : 136
TERMS

CAS Newton
Get started faster with CAS NewtonSM
Our new AI chat experience helps you
discover insights quicker. [Learn more.](#)
Ask CAS Newton

Display a delimited
list for copy & paste
and manage in, e.g.,
Microsoft Excel.

L17 = CAS results


L22 = DWPI results

L23 = Merged results

L24 = List of Basic
Publication Numbers
with Kind Code (PNK.B)

Keep Track of Your CAS IP Finder PN lists

For example, using Microsoft Excel



Option: Create different PN lists using ANALYZE to upload into PatBase in a more stepwise workflow

E.g., you may wish to review MARPAT results independently of the rest of the results

Upload the CAS IP Finder Publication Numbers

Publication

Application

Family

Upload publication numbers

Please enter publication numbers to be searched.
Publication numbers should be separated by a line break or a delimiter.

WO2026132305 A1
WO2026125637 A1
WO2026125634 A1
WO2025220032 A1
WO2025151884 A1
WO2025144919 A1
WO2025097068 A1
WO2025046589 A1
WO2024155958 A1
WO2024141760 A1
WO2024079739 A1
WO2024079738 A1
WO2024050289 A1
WO2023287117 A1
WO2023174433 A1
WO2023121822 A1

Upload

Clear

Example

Delimiter: Line break

☒ Create hit report

Publication number upload report

Showing: All

Export to Excel

Search All Included

	Input	Family	Resolved	Granted	Pub Date	Probable Assignee	Title	☒
	WO2026132305 A1	113517672	WO26132305 A1	X	2026-06-25	SPACE PHARMACEUTICALS AG	IMPROVED FORMULATION FOR BUCCAL MUCOSAL DRUG DELIVERY	☒
	WO2026125637 A1	106578183	WO26125637 A1	X	2026-06-18	ALGIPHARMA AS	COMBINATIONS OF GASTROINTESTINAL PERMEATION ENHANCERS FOR USE IN COMPOSITIONS AND METHODS TO ENHANCE THE SYSTEMIC	☒

- Upload the CAS IP Finder publication numbers to PatBase using *Search > Upload numbers*
- Review the *Publication number upload* report
- Click *Search All included*

Extending the Search in PatBase

Search History

Save Search History Clear Search History Export Search History

#	Search query	Results	Options
1	PN=(WO9834632 A1 OR WO9747270 A2 OR WO26132305 A1 OR WO26125637 A1 OR WO26125634 A1 OR WO26092429 A1 OR WO25220032 A1 OR WO25151884 A1 OR WO25146144 A1 OR WO25144919 A1 OR WO25097068 A1 OR WO25046589 A1 OR WO24155958 A1 OR WO24141760 A1 OR WO24097926 A1 OR WO24079739 A1 OR WO24079738 A1 OR WO24077409 A1 OR WO24050289 A1 OR WO23287117 A1 OR WO23174433 A1 OR WO23161939 A1 OR WO23161938 A1 OR WO23161937 A1 OR WO23161936 A1 OR WO23161935 A1 OR WO23161934 A1 OR WO23161933 A1 OR WO23123063 A1 OR WO... show full search	119	View Browse Hits Optimise Export More...
2	atac=(5_CNAC or (chloro_salicyloyl or chloro w3 hydroxy w3 benzoyl or hydroxy w3 chlorobenzoyl or chloro w3 hydroxybenzoyl) wf2 (amino_caprylic or amino_octanoic or amino_caproate or amino_octanoate))	98	View Browse Hits Optimise Export More...
3	aft=((permeation or penetration or absorption or (drug% or pharmaceutical% or active wf2 (agent% or substance%)) w5 deliver*) w5 (enhanc* or improv* or system%))	1,068,641	View Browse Hits Optimise Export More...
4	aft=((skin or dermis or dermal or epidermis or epidermal or transdermal or intestine or intestinal or gastrointestinal or duodenum or jejunum or ileum or colon or epithelium or epithelial or transepithelial or stomach or mucosa or mucosal or transmucosal) w5 (enhanc* or improv*))	482,871	View Browse Hits Optimise Export More...
5	2 and (3 or 4)	86	View Browse Hits Optimise Export More...
6	5 not 1	8	View Browse Hits Optimise Export More...
7	(1 or 5) and CC=(EP or US or JP or KR or CN or WO)	125	View Browse Hits Optimise Export More...
8	7 and prd>=20050914	111	View Browse Hits Optimise Export More...

Conduct a title, abstract, claims (ATAC=), and/or a full text (AFT=) search

8 additional results were found by adding PatBase text search (Search 6)


Limit e.g., by patent authorities and/or priority dates as needed

In the end 111 results are ready to be reviewed (Search 8)

FTO Exploration with CAS IP Finder

How it fits into in a professional IP search workflow

- Introduction
- FTO vs Patentability: Brief overview
- Search example: 5-CNAC
- CAS IP Finder: Search and results review
- PatBase: Import CAS IP Finder PNs and search steps
- **Analysis, record selection, reporting**
- Closing remarks, Q&A



Reviewing in PatBase


PatBase’s general overview provides a customizable interface for assessing search results

23Family number: 101556210 (WO24050289 A1)

SimilarTranslateFull-textStatusCitationsInsight (5.9%)

Title

[EN] COMPOSITIONS FOR ORAL DELIVERY
[FR] COMPOSITIONS POUR ADMINISTRATION ORALE



Classifications

Classification Explorer

IPC: A61K38/02; A61K38/16; A61K38/26; A61K47/12; A61K47/18; A61K47/32; A61K47/38; A61K9/48; A61K9/52; A61P1/16; A61P25/16; A61P25/28; A61P3/04; A61P3/06; A61P3/10; A61P43/00; A61P9/00; C07K14/605; C07K16/18

CPC: A61K38/26; A61K9/4808; A61K9/4883; A61K9/4891; A61P3/10; C07K14/605

JP F-Term: 4C076; 4C084; 4C201; 4H045; 4C076/AA60; 4C076/BB01; 4C076/CC01; 4C076/CC11; 4C076/CC16; 4C076/CC21; 4C076/DD41.N; 4C076/DD51.N; 4C076/EE10.J; 4C076/EE12.J; 4C076/EE31; 4C076/FF68; 4C076/GG16; 4C084/ZA16; 4C084/ZA36; 4C084/ZA70; 4C084/ZA75; 4C084/ZC21; 4C084/ZC33; 4C084/ZC35; 4C084/ZC41; 4H045/AA10; 4H045/AA30; 4H045/BA19; 4H045/CA40; 4H045/DA30; 4H045/EA30; 4H045/FA10; 4H045/GA45

Family

Family Explorer

Publication number	Publication date	Application number	Application date	
AR130332 AA	20241127	AR2023P102289	20230829	☐
AU2023333905 AA	20250320	AU20230333905	20230828	☐
BR112025003839 A2	20250902	BR202511003839	20230828	☐
CA3266547 AA	20240307	CA20233266547	20230828	☐
CL2025000555 A0	20250227	CL20250000555	20250227	☐
CL2025000555 A1	20250509	CL20250000555	20250227	☐

<< Previous1-1 of 1Next >>

Abstract

[EN] The present invention relates to a dosage form suitable for oral administration comprising a therapeutic peptide or protein in a sealed capsule having a co-polymer coating.

[FR] La presente invention concerne une forme posologique appropriée pour une administration orale comprenant un peptide ou une protéine thérapeutique dans une capsule scellée ayant un revêtement copolymère.

Keyword in context (KWIC)

Claims WO24050289 A1 **6** **1**

The dosage form of any of claims 1-26 wherein the core composition further comprises a **permeation enhancer**.

The dosage form of claim 27 wherein the **permeation enhancer** is selected from the group consisting of sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), sodium caprate (CIO), sodium caprylate (C8), and 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (**5-CNAC**).

The dosage form of any of claims 27-28 wherein the **permeation enhancer** is CIO.

Reviewing in PatBase – Full Text View

Full text view

Active highlighting: Advanced Highlighting

Edit

Cancel

View biblio.

Hit Analysis

☐ Hide publications with no hits

☐ **AU2024370337 AA**

- Title/Abstract (5)

- Claims (24)

- Description (127)

☐ **CA3309985 AA**

- Title/Abstract (5)

☐ **EP4801477 A1**

- Title/Abstract (5)

- Claims (28) **smart**

- Description (210)

☐ **IL328013 AA**

- Title/Abstract (5)

- Claims (27) **smart**

- Description (210)

☐ **NZ832301 A**

- Title/Abstract (5)

☐ **WO25097068 A1**

- Title/Abstract (5)

- Claims (28) **smart**

- Description (210)

Country filter: ☒ All ☐ Countries:

Publication filter: ☒ All ☐ Grants only **Apply**

Sections filter: ☒ All ☐ Document sections: ☐ Title/Abstract ☐ Claims ☐ Description

Hit analysis

Copy table

Publication									
AU2024370337 AA (Title/Abstract) »	5								
AU2024370337 AA (Claims) »	18	6							
AU2024370337 AA (Description) »	121	6							
CA3309985 AA (Title/Abstract) »	5								
EP4801477 A1 (Title/Abstract) »	5								
EP4801477 A1 (Claims) »	22	6							
EP4801477 A1 (Description) »	201	9							
IL328013 AA (Title/Abstract) »	5								
IL328013 AA (Claims) »	22	5							
IL328013 AA (Description) »	201	9							
NZ832301 A (Title/Abstract) »	5								
WO25097068 A1 (Title/Abstract) »	5								
WO25097068 A1 (Claims) »	22	6							
WO25097068 A1 (Description) »	201	9							

Legend

(skin or dermis or dermal or epidermis or epidermal or transdermal or intestine or intestinal or gastrointestinal or duodenum or jejunum or ileum or colon or epithelium or epithelial or transepithelial or stomach or mucosa or mucosal or permeation or penetration or absorption or (drug or pharmaceutical or active wf1 (agent or substance)) w5 deliver*) w5 (enhanc* or improv*)
5_CNAC or (chloro_salicyloyl or chloro wf2 hydroxy_benzoyl) wf2 (amino_caprylic or amino_octanoic)

AU2024370337 AA

Title/Abstract **5**

ORAL DOSAGE FORM WITH IONICALLY CHARGEABLE HYDROGEL FOR **DELIVERY** OF **ACTIVE AGENT** AND **PERMEATION ENHANCER**

Claims **18** **6**

The dosage form according to any preceding claim, wherein the **permeation** **20 enhancer** comprises salcaprozic acid or a salt thereof.

The dosage form according to any preceding claim, comprising no more than 500 30 mg, no more than 400 mg, and/or no more than 300 mg of **permeation enhancer** and 29.

The dosage form according to any preceding claim, comprising from 100 mg to 400 mg of **permeation enhancer** and/or from 200 to 300 mg of **permeation enhancer**.

The dosage form according to any preceding claim, further comprising an additional **permeation enhancer** that is any selected from **5-CNAC** ((N-(5- **chlorosalicyloyl**)-8- **aminocaprylic** acid), cell penetrating peptides such as penetratin and 97 wo 2025/097068 PCT/US2024/054286 21.

Reviewing in PatBase – Full Text View

Full text view Active highlighting: Advanced Highlighting **Edit** Cancel

View biblio.

Hit Analysis

☐ Hide publications with no hits

☒ AU2024370337 AA

Title/Abstract (5)

Claims (24)

Description (127)

☒ CA3309985 AA

Title/Abstract (5)

WO25097068 A1 - Claims **permeation enhancer**

29. The dosage form according to any preceding claim, comprising from 100 mg to 400 mg of **permeation enhancer** and/or from 200 to 300 mg of **permeation enhancer**.

30. The dosage form according to any preceding claim, further comprising an additional **permeation enhancer** that is any selected from **5-CNAC** ((N-(5- **chlorosalicyloyl**)-8- **aminocaprylic** acid), cell penetrating peptides such as penetratin and 1084242.000041 PentraMax™, sucrose laurate, polyoxyethylene-8 lauryl ether, macrogol-8 glycerides, Labrasol(R), clostridium perfringens enterotoxin (C-CPE), pelargonidin, phenoxyethanol, phenyl ethanol, benzyl alcohol, tetradecylmaltoside, claudin-153-80 peptide, occludin peptides, cytochalasin, tryptophan, PN159 (peptide: KLALKLALKALKALKLA-amide), capsaicin, viral protein 8 (VP8), Pep1 (C-terminal-amidated peptide (FCIGRL-NH2)), CriticalSorb™, and citric acid or pharmaceutically acceptable salts thereof.

31. The dosage form according to any preceding claim, further comprising one or more protease inhibitors selected from the group consisting of a soybean trypsin inhibitor, ethylenediaminetetraacetic acid (EDTA), citric acid, aprotinin, camostat mesylate, bacitracin, a pancreatic inhibitor, a chymotrypsin inhibitor such as FK-448 and chymostatin, a Bowman-Birk inhibitor, and pharmaceutically acceptable salts thereof.

32. The dosage form according to any preceding claim, wherein the active agent comprises any selected from the group consisting of GLP-1 agonists, GIP agonists, GIP/GLP-1 co-agonists, and

Hit Map - Show terms »

- To assess relevance, it is important to review the examples and supporting disclosure to understand the role of the substance within the invention and whether it is presented as a key embodiment, a preferred compound, or merely one option among many alternatives.

38

© 2026 American Chemical Society. All rights reserved.

CAS

A division of the
American Chemical Society

Reviewing in PatBase – Full Text View

Full text view Active highlighting: Advanced Highlighting Edit Cancel

[View biblio](#) [Hit Analysis](#)

☐ Hide publications with no hits

☒ CN118647386 A
 -Title/Abstract
 -Claims **smart**
 -Description (10)

☐ EP4444322 A1
 -Title/Abstract
 -Claims **smart**
 -Description (10)

☐ EP4444322 A4
 -Title/Abstract

☐ US2023338413 AA
 -Title/Abstract
 -Claims **smart**
 -Description (10)

☐ WO23102690 A1
 -Title/Abstract
 -Claims **smart**
 -Description (10)

Country filter: ☒ All ☐ Countries: US WO EP Publication filter: ☒ All ☐ Grants only Apply
 Sections filter: ☒ All ☐ Document sections: ☐ Title/Abstract ☐ Claims ☐ Description

Hit analysis

Publication	10	10	10	10	10	10	10	10	10	10	10
CN118647386 A (Description) »	10										
EP4444322 A1 (Description) »	10										
US2023338413 AA (Description) »	10										
WO23102690 A1 (Description) »	10										

Copy table

Legend

(skin or dermis or dermal or epidermis or epidermal or transdermal or intestine or intestinal or gastrointestinal or duodenum or jejunum or ileum or colon or epithelium or epithelial or transepithelial or stomach or mucosa or mucosal or permeation or penetration or absorption or (drug or pharmaceutical or active w/1 (agent or substance) w/5 deliver*) w/5 (enhanc* or improv*)

5_CNAC or (chloro_salicyloyl or chloro w/2 hydroxy_benzyoyl) w/2 (amino_caprylic or amino_octanoic)

CN118647386 A

Description 10

In various embodiments, the disclosure is based in part on the unexpected discovery that a combination of certain fatty acids and oral **absorption enhancers** can achieve synergistic effects in **enhancing** overall oral **absorption** of heparin.

Typically, pharmaceutical compositions contain two or more functional excipients that synergistically **enhance** the oral **absorption** of heparin.

purposes, e.g., acting as carriers, vehicles, fillers, binders, lubricants, glidants, disintegrants, Flow control agents, crystallization retarders, solubilizers, stabilizers, colorants, flavoring agents, surfactants, enzyme inhibitors, Alkalinizing agents, acidifying agents and/or to **improve** the application and/or **absorption** of active substances, tablet coating agents to control the dissolution rate of solid dosage forms according to the pH in the gastrointestinal tract.

A common approach is to combine peptidase inhibitors with absorption modifying excipients or chemical **penetration enhancers** (PE).

EP4444322 A1

Description 10

[0007] In various embodiments, the present disclosure is based, in part, on the unexpected discovery that the combination of certain fatty acids and oral **absorption enhancers** can achieve a synergistic effect in **enhancing** overall oral **absorption** of heparin.

Full text view Active highlighting: Advanced Highlighting Edit Cancel

[View biblio](#) [Hit Analysis](#)

☐ Hide publications with no hits

☐ CN118647386 A
 -Title/Abstract
 -Claims **smart**
 -Description (2)

☐ EP4444322 A1
 -Title/Abstract
 -Claims **smart**
 -Description (2)

☐ EP4444322 A4
 -Title/Abstract

☐ US2023338413 AA
 -Title/Abstract
 -Claims **smart**
 -Description (2)

☐ WO23102690 A1
 -Title/Abstract
 -Claims **smart**
 -Description (2)

WO23102690 A1 - Claims

Translate textmine AI Summary Compare

A pharmaceutical composition comprising:

(a) a low molecular weight heparin (LWMH);

(b) an aliphatic acid of Formula I: RCOOH, wherein R represents an aliphatic group, or a pharmaceutically acceptable salt thereof, and

(c) a compound of Formula II:

Formula II

or a pharmaceutically acceptable salt thereof, wherein: n is an integer selected from 0, 1, 2, 3, or 4;

G¹ at each occurrence is independently OH, NH₂, NH (C₁₋₄ alkyl), N (C₁₋₄ alkyl) (C₁₋₄ alkyl), halogen (e.g., Cl), C₁₋₄ alkyl, or C₁₋₄ alkoxy (e.g., OCH₃); and

L¹ is a substituted or unsubstituted C₂₋₁₆ alkylene, or substituted or unsubstituted C₂₋₁₆ alkenylene.

- Using the double screen option in full text review to ease document review.

Reviewing in PatBase


1 Family number: 113517672 (WO26132305 A1)

Similar Translate Full-text Status Citations Insight (1.8%) 

Title

[EN] IMPROVED FORMULATION FOR BUCCAL MUCOSAL DRUG DELIVERY

[FR] FORMULATION AMELIOREE POUR L'ADMINISTRATION DE MEDICAMENTS PAR VOIE MUQUEUSE BUCCALE



Abstract

[EN] The invention relates to the field of therapeutic agent delivery using suction-cup orifice design (SCOD) as a vehicle. In particular, the invention provides new formulations for semaglutide delivery using SCOD that shows greater bioavailability across the buccal mucosa. This invention also provides methods of preparing these compositions.

[FR] L'invention concerne le domaine de l'administration d'agents thérapeutiques utilisant une conception d'orifice à ventouse (SCOD) comme vecteur. En particulier, l'invention fournit de nouvelles formulations pour l'administration de semaglutide utilisant le SCOD, présentant une plus grande biodisponibilité à travers la muqueuse buccale. La présente invention fournit également des méthodes de préparation de ces compositions.

Export Possibilities

Family Number	Title	Abstract	Dead or Alive	Priority Numbers	Priority Dates	Keywords in Context
118517672	[EN] IMPROVED FORMULATION FOR BUCCAL MUCOSAL DRUG DELIVERY	[EN] The invention relates to the field of therapeutic agent delivery using suction-cup orifice design (SCOD) as a vehicle. In particular, the invention provides new formulations for semaglutide delivery using SCOD that shows greater bioavailability across the buccal mucosa. This invention also provides methods of preparing these compositions.	ALIVE	EP20240221323	2024-12-18	Claims 5 34 A mucosal suction cup comprising a composition comprising a therapeutic agent and at least one permeation enhancer , wherein the permeation enhancer is selected from a bile salt, a compound having a steroid skeleton, a fatty acid, a surfactant (natural or synthetic), a chelator, a positively charged polymer, a cyclodextrin, thiomethanol, a
76964679	[EN] ORAL MUCOSAL DELIVERY SYSTEMS COMPRISING MONOPHASIC CONCENTRATE OF TERIPARATIDE	[EN] This invention comprises a water free liquid composition comprising Teriparatide for transmucosal delivery that adheres to mucosa after coming in contact with mucosal surface and a system of making dosage form from the same and delivering to mucous membrane at various locations through liquid drops, capsule or tablets. The liquid composition is characterized by being a monophasic composition. The liquid monophasic	ALIVE ALIVE	IN201821021663 WO2019IN50444	2018-06-10 2019-06-10	Abstract 4 The liquid monophasic composition comprises a non-aqueous liquid as carrier, a penetration enhancer/permeation enhancer , stabilizer and a surfactant.
104619808	[EN] A HIGH BIOAVAILABILITY PHARMACEUTICAL COMPOSITION OF GLP AGONIST FOR ORAL ADMINISTRATION	[EN] The present invention relates to a pharmaceutical composition for oral administration comprising a GLP receptor agonist or pharmaceutically acceptable salt or derivatives thereof, one or more medium chain fatty acid based permeation enhancers with aromatic functional group, and one or more medium chain fatty acid based permeation enhancers without aromatic functional group. The	ALIVE ALIVE	IN202321020795 WO20241B52151	2023-03-23 2024-03-06	Claims 20 Abstract 4 The present invention relates to a pharmaceutical composition for oral administration comprising a GLP receptor agonist or pharmaceutically acceptable salt or derivatives thereof, one or more medium chain fatty acid based permeation enhancers with aromatic functional group, and one or more medium chain fatty acid based permeation enhancers
104619814	[EN] A PHARMACEUTICAL COMPOSITION OF GLP AGONIST FOR ORAL ADMINISTRATION	[EN] The present invention relates to a pharmaceutical composition for oral administration comprising a GLP receptor agonist or pharmaceutically acceptable salt or derivatives thereof, one or more permeation enhancer , one or more mucoadhesive agent and one or more basifier. More preferably, permeation enhancer are medium chain fatty acid based permeation enhancers .	ALIVE ALIVE	IN202321020778 WO20241B52155	2023-03-23 2024-03-06	Abstract 6 The present invention relates to a pharmaceutical composition for oral administration comprising a GLP receptor agonist or pharmaceutically acceptable salt or derivatives thereof, one or more permeation enhancer , one or more mucoadhesive agent and one or more basifier.
105392115	[EN] STABLE AND BIOAVAILABLE PHARMACEUTICAL FORMULATIONS OF SEMAGLUTIDE	[EN] The present invention relates to stable and bioavailable pharmaceutical formulations useful for the oral administration comprising Semaglutide and one or more permeation enhancers , and process for their preparation. Oral administration of the formulations of the present invention can be used for the treatment of type 2 diabetes as well as a variety of other conditions.	ALIVE	IN202311033485	2023-05-12	Abstract 2 The present invention relates to stable and bioavailable pharmaceutical formulations useful for the oral administration comprising Semaglutide and one or more permeation enhancers , and process for their preparation.
107899279	[EN] MINOXIDIL ADJUVANT THERAPIES	[EN] Compositions and methods are disclosed herein for inducing (up-regulating) the expression and/or activity of sulfotransferases in the hair follicles, e.g., the scalp. The compositions include (i) an agent configured to increase the sulfonating ability of hair bearing skin, hair follicles, and/or keratinocyte cells in a person; (ii) an alkalinizing agent; (iii) liposomes encapsulating at least some of the alkalinizing agent; (iv) an antioxidant.	ALIVE	US20230594884P	2023-10-31	Claims 6 Abstract 2 Additional methods and compositions include the use of the topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells.
65976766	[EN] COMPOSITION FOR INTRAORAL DELIVERY OF BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS	[EN] The present disclosure relates to self-emulsifying pharmaceutical compositions for transmucosal delivery of biologically active peptides and proteins.	DEAD DEAD DEAD ALIVE ALIVE	US20150241327P WO20161B02013 US20160768758 US20180768758 US20250053696	2015-10-14 2016-10-14 2016-10-14 2018-04-16 2025-02-14	Claims 4 A solid dosage form containing a composition of claim 1, said dosage form may further comprise physiologically acceptable excipients, such as sweeteners, absorbents, fillers, binders, penetration enhancers , antioxidants, preservatives, stabilizers, flavors, coating components,

Export Possibilities

- Customizable views and reporting fields tailored to specific review needs.
- Flexible highlighting improves review efficiency and communication of key findings.

1. Family 113517672 (WO26132305 A1)

[View in PatBase](#)

Title

[EN] **IMPROVED** FORMULATION FOR BUCCAL **MUCOSAL** DRUG DELIVERY

Abstract

[EN] The invention relates to the field of therapeutic agent delivery using suction-cup orifice design (SCOD) as a vehicle. In particular, the invention provides new formulations for semaglutide delivery using SCOD that shows greater bioavailability across the buccal mucosa. This invention also provides methods of preparing these compositions.

Priority Numbers: EP20240221323 [20241218]

Assignees: SPACE PHARMACEUTICALS AG

Inventors: HE RUNZE; GAN BEE HA

1st Main Claim

[EN] New PCT Patent Application Space Pharmaceuticals AG Vossius Ref.: AJ2733 PCT BS CLAIMS 1. A mucosal suction cup comprising a composition comprising a therapeutic agent and at least one **permeation enhancer**, wherein the **permeation enhancer** is selected from a bile salt, a compound having a steroid skeleton, a fatty acid, a surfactant (natural or synthetic), a chelator, a positively charged polymer, a cyclodextrin, thiomenthol, a polysorbate and any combination thereof.


Keywords in Context

Title 2

IMPROVED FORMULATION FOR BUCCAL **MUCOSAL** DRUG DELIVERY

Claims 35 15

A mucosal suction cup comprising a composition comprising a therapeutic agent and at least one **permeation enhancer**, wherein the **permeation enhancer** is selected from a bile salt, a compound having a steroid skeleton, a fatty acid, a surfactant (natural or synthetic), a chelator, a positively charged polymer, a cyclodextrin, thiomenthol, a polysorbate and any combination thereof.



CAS IP Services Reporting

- Flexible deliverables, including customized Word and Excel reports generated directly from PatBase.
- To support comprehensive FTO assessments, additional Markush search hits can be incorporated to provide structure highlighting from CAS IP Finder.
- Results can be shared directly through PatBase folders, giving clients immediate access to reviewed document sets and supporting collaboration.

Summary

- Define target molecule and leverage CAS IP Finder structure search with manually curated CAS and DWPI indexing to maximize recall and precision
- Utilize value-added patent databases in CAS IP Finder to identify relevant patent families, compounds, and ownership information
- Export search results to PatBase for additional full text search, analysis and review
- Make use of multi-color highlighting and other review features to rapidly assess relevance and key claim disclosures
- Export relevant patent documents to Word or Excel, including critical fields such as publication number, assignee, priority date, legal status, claims, and relevance notes

Trust CAS IP ServicesSM

For quality insights delivered on time

Unmatched human expertise

25+ years average researcher experience within global R&D companies

Unparalleled scientific & IP content

Access to unique CAS and third-party content

Specialized technology

Extensive knowledge of patent and scientific search technologies and resources

Industry expertise



Exemplified and Markush Chemical Structures



Protein and Nucleic Acid Biosequences



Chemistry, Biotechnology, and Materials Sciences



Biomedical Devices



Engineering




Minesoft was delighted to support CAS as part
of today's webinar session

For any specific questions on PatBase or any
other Minesoft products,
please contact:

support@minesoft.com

Disclaimer

The materials provided in this presentation are for informational purposes only and do not constitute legal advice. These materials reflect only the personal views of the authors and are not the views of ACS, CAS or FIZ Karlsruhe. While every attempt was made to ensure that these materials are accurate, errors or omissions may be contained therein, for which any liability is disclaimed.



Thank you

Robert Austin

Senior Customer Success Specialist
RAustin@acs-i.org

Dr. João Jacinto

Information Specialist
IPServices@cas.org
CAS IP Services (EMEA) – Represented by FIZ Karlsruhe

| Connect with us at cas.org



linkedin.com/company/cas



@CASchemistry

